Supplementary Table 1 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 28K, Growth inhibitory IC50s of indicated compounds in parental and erlotinib-TR HCC827 cells.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362494276